- Home
- WSBF vs AVIR Comparison
WSBF vs AVIR Comparison
Compare WSBF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- AVIR
- Stock Information
- Founded
- WSBF 1921
- AVIR 2012
- Country
- WSBF United States
- AVIR United States
- Employees
- WSBF N/A
- AVIR N/A
- Industry
- WSBF Savings Institutions
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- WSBF Finance
- AVIR Health Care
- Exchange
- WSBF Nasdaq
- AVIR Nasdaq
- Market Cap
- WSBF 296.4M
- AVIR 247.5M
- IPO Year
- WSBF N/A
- AVIR 2020
- Fundamental
- Price
- WSBF $13.63
- AVIR $3.26
- Analyst Decision
- WSBF
- AVIR Hold
- Analyst Count
- WSBF 0
- AVIR 1
- Target Price
- WSBF N/A
- AVIR $6.88
- AVG Volume (30 Days)
- WSBF 42.3K
- AVIR 503.8K
- Earning Date
- WSBF 01-28-2025
- AVIR 11-07-2024
- Dividend Yield
- WSBF 4.46%
- AVIR N/A
- EPS Growth
- WSBF 40.34
- AVIR N/A
- EPS
- WSBF 0.71
- AVIR N/A
- Revenue
- WSBF $133,232,000.00
- AVIR N/A
- Revenue This Year
- WSBF N/A
- AVIR N/A
- Revenue Next Year
- WSBF N/A
- AVIR N/A
- P/E Ratio
- WSBF $19.10
- AVIR N/A
- Revenue Growth
- WSBF N/A
- AVIR N/A
- 52 Week Low
- WSBF $10.60
- AVIR $2.75
- 52 Week High
- WSBF $16.86
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- WSBF 25.40
- AVIR 53.11
- Support Level
- WSBF $13.30
- AVIR $3.10
- Resistance Level
- WSBF $14.97
- AVIR $3.32
- Average True Range (ATR)
- WSBF 0.37
- AVIR 0.14
- MACD
- WSBF -0.16
- AVIR 0.03
- Stochastic Oscillator
- WSBF 9.16
- AVIR 87.61
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).